liraglutide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 112 Diseases   125 Trials   125 Trials   6082 News 


12345678910111213...6465»
  • ||||||||||  liraglutide / Generic mfg., metformin / Generic mfg., topiramate / Generic mfg.
    Journal, Adverse drug reaction:  Metabolic adverse drug reactions related to psychotropic drugs (Pubmed Central) -  Mar 12, 2025   
    Lifestyle modification, dietary measures, exercise therapy, dose reduction, change and discontinuation of the substance, and additional treatment with metformin and topiramate are evidence-based treatment options for AP-associated weight gain. GLP-1 receptor agonists such as liraglutide are also promising.
  • ||||||||||  PERMEABILITY OF THE BLOOD-BRAIN BARRIER TO INCRETIN RECEPTOR AGONISTS (Hall B) -  Mar 10, 2025 - Abstract #ADPD2025ADPD_760;    
    Four IRAs (liraglutide, DA1-JC, semaglutide, and tirzepatide) have very low or no measurable uptake...There was a correlation between absolute charge and BBB penetration, suggesting uptake by the mechanism of adsorptive transcytosis. Conclusions These results suggest that some IRAs may exert neuroprotective effects by acting behind the BBB.
  • ||||||||||  DUAL GLP-1/GIP RECEPTOR AGONISTS THAT CAN CROSS THE BBB SHOW SUPERIOR NEUROPROTECTIVE EFFECTS (Hall B) -  Mar 10, 2025 - Abstract #ADPD2025ADPD_758;    
    Conclusions These results suggest that some IRAs may exert neuroprotective effects by acting behind the BBB. Methods Bydureon (exenatide) and Adlyxin (lixisenatide) showed disease-modifying protective effects in patients with PD in two phase 2 clinical trials...NLY01, a pegylated form of exenatide that can
  • ||||||||||  liraglutide / Generic mfg.
    CLINICAL EVALUATION OF GLP-1 ANALOGUES IN ALZHEIMER (Hall B) -  Mar 10, 2025 - Abstract #ADPD2025ADPD_757;    
    Aims Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue licensed for the treatment of type 2 diabetes mellitus (T2DM)...This was associated with slower decline in cognitive function. Conclusions These findings highlight the potential of GLP-1 analogues in the treatment of Alzheimer
  • ||||||||||  liraglutide / Generic mfg.
    Preclinical, Journal:  Liraglutide modulates ALCAT1-Mediated cardiolipin remodeling to improve cardiac function in obese mice. (Pubmed Central) -  Mar 9, 2025   
    These results demonstrate that liraglutide mitigates obesity-induced cardiac dysfunction by suppressing ALCAT1-driven CL remodeling, enhancing mitochondrial homeostasis, and reducing oxidative stress. This study elucidates the cardioprotective mechanisms of liraglutide and highlights its therapeutic potential for obesity-related cardiomyopathy.
  • ||||||||||  liraglutide / Generic mfg.
    Review, Journal:  The effect of glucagon-like Peptide-1 receptor agonists on measures of suicidality: A systematic review. (Pubmed Central) -  Mar 9, 2025   
    Pharmacovigilance studies indicate that semaglutide and liraglutide are associated with disproportionate reporting of SI...Ongoing vigilance and further information is required to inform if the possibility of causality exists. Practitioners prescribing GLP-1 RAs should be vigilant for the possibility of the emergence of SI and be aware of the higher risk of mental illness in persons who would be candidates for GLP-1 RAs (e.g. Type 2 Diabetes, obesity).
  • ||||||||||  liraglutide subcutaneous prolonged-release (NEX-22) / Nanexa AB
    Enrollment open:  Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D (clinicaltrials.gov) -  Mar 6, 2025   
    P1,  N=12, Recruiting, 
    Future large-scale, high-quality clinical trials are needed to validate these findings and further optimize comprehensive cardiovascular management strategies for patients. Active, not recruiting --> Recruiting
  • ||||||||||  Journal:  Fusion Outcomes of GLP-1 Agonist Therapy in Multilevel Cervical Spinal Fusion: A Propensity-Matched Analysis. (Pubmed Central) -  Mar 5, 2025   
    Fundamentally, this aligns with the pharmacodynamic nature of GLP-1 agonists: as compounds that enhance osteoblastic activity and suppress osteoclastic activity, thereby facilitating bone formation and attenuating bone resorption. Further investigation into the mechanistic underpinnings of GLP-1 agonists' effects on bone metabolism may pave the way for enhancing the success of cervical spine surgery.
  • ||||||||||  Journal, Adverse events:  Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis. (Pubmed Central) -  Mar 5, 2025   
    DPP-4 inhibitors are potentially linked to biliary disorders, warranting vigilance. While the overall association for GLP-1 RAs was not significant, specific drugs like semaglutide, liraglutide, and sitagliptin showed concerning signals, suggesting a need for heightened awareness among clinicians regarding the risk of biliary AEs.
  • ||||||||||  liraglutide / Generic mfg.
    Trial completion:  STARDUST: Liraglutide and Peripheral Artery Disease (clinicaltrials.gov) -  Mar 3, 2025   
    P4,  N=60, Completed, 
    SGLT-2i appear more effective in the improvement of neurohumoral and mitochondrial activation. Recruiting --> Completed
  • ||||||||||  P2 data, Review, Journal:  The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines. (Pubmed Central) -  Mar 1, 2025   
    A combination of semaglutide (a GLP-1 agonist) and cagrilintide (a long-acting amylin analogue) for weekly administration is currently in phase III development, and so is oral semaglutide and several non-peptide small molecule GLP-1 agonists for oral administration...The GLP-1-based therapies will change the treatment of obesity and its comorbidities including steatotic liver disease in the future. Outstanding question is maintenance of the weight loss, possibly pharmacological treatment needs to be life-long.
  • ||||||||||  liraglutide / Generic mfg., Mounjaro (tirzepatide) / Eli Lilly
    Review, Journal:  The Promise of Adjunct Medications in Improving Type 1 Diabetes Outcomes: Glucagon-Like Peptide Receptor Agonists. (Pubmed Central) -  Mar 1, 2025   
    Common side effects include gastrointestinal issues, and while some studies reported hypoglycemia, hyperglycemia, and ketosis, others did not. Despite these challenges, GLP-1 RAs offer significant therapeutic benefits, making them a promising adjunct to insulin therapy for improving clinical outcomes in T1D management.
  • ||||||||||  Mounjaro (tirzepatide) / Eli Lilly
    Journal:  Expectations and Outcomes From Glucagon-Like Peptide-1 Receptor Agonists As Adjunct Treatment for Type 1 Diabetes - Case Presentations. (Pubmed Central) -  Mar 1, 2025   
    This case series investigates the effectiveness of GLP-1 RAs, mainly semaglutide and tirzepatide, as an adjunct therapy to insulin in adolescents and young adults (AYA) with T1D, in a single center, providing real-world insights and highlighting practical issues...Glycemic parameters improved in most patients, with weight reduction in several patients with obesity, and no reported diabetic ketoacidosis. GLP-1 RAs can be a beneficial adjunct therapy in T1D, improving glycemic control, reducing insulin needs, and supporting weight management, while potentially preventing long-term cardiovascular and renal complications.
  • ||||||||||  liraglutide / Generic mfg., Byetta (exenatide) / AstraZeneca, Trulicity (dulaglutide) / Eli Lilly
    Preclinical, Journal:  Dulaglutide accelerates diabetic wound healing by suppressing Nrf2-dependent ferroptosis in diabetic mice. (Pubmed Central) -  Feb 27, 2025   
    Mechanistically, dulaglutide activated NFE2-related factor 2 (Nrf2) signaling under HG conditions, which increased glutathione peroxidase (Gpx4) and solute carrier family 7-member 11 (Slc7a11) expression, thereby inhibiting ferroptosis. In summary, these results demonstrate dulaglutide as a promising agent for treating diabetic wounds by regulating Nrf2-dependent ferroptosis.
  • ||||||||||  Meridia (sibutramine) / AbbVie, Xenical (orlistat) / Roche, GSK, Byetta (exenatide) / AstraZeneca
    Clinical, Retrospective data, Review, Journal:  Pharmacological interventions for addressing pediatric and adolescent obesity: A systematic review and network meta-analysis. (Pubmed Central) -  Feb 27, 2025   
    In summary, these results demonstrate dulaglutide as a promising agent for treating diabetic wounds by regulating Nrf2-dependent ferroptosis. The study found that semaglutide outperformed other AOMs in reducing BMI and additional weight-related outcomes in children and adolescents with obesity, while PHEN/TPM showed comparable efficacy.
  • ||||||||||  liraglutide / Generic mfg.
    Review, Journal:  A comprehensive review on liraglutide and novel nanocarrier-based systems for the effective delivery of liraglutide. (Pubmed Central) -  Feb 27, 2025   
    These nanocarriers facilitate site-specific and sustained release of liraglutide, improving its bioavailability and therapeutic efficacy. This article provides a comprehensive overview of liraglutide's pharmacological properties, preclinical studies, and the potential of different nanocarrier-based approaches in optimizing its delivery for enhanced clinical outcomes.
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Journal:  A renal indication for semaglutide (Ozempic). (Pubmed Central) -  Feb 27, 2025   
    This article provides a comprehensive overview of liraglutide's pharmacological properties, preclinical studies, and the potential of different nanocarrier-based approaches in optimizing its delivery for enhanced clinical outcomes. No abstract available
  • ||||||||||  Byetta (exenatide) / AstraZeneca, Trulicity (dulaglutide) / Eli Lilly
    Cutaneous Adverse Events of Glucagon-Like-Peptide-1 (GLP-1) Agonists () -  Feb 26, 2025 - Abstract #AAD2025AAD_3465;    
    In addition, the literature includes few reports of eosinophilic panniculitis (n=10)3, bullous pemphigoid (n=3)4,5,6, morbilliform drug eruption (n=2)7,8, angioedema (n=2)9,10, pyoderma gangrenosum (n=1)11, vesiculopustular dermatosis (n=1)12, psoriasiform drug eruption (n=1)13, and acute photodistributed exanthematous pustulosis (n=1)14. Conclusion Further research is needed to better understand the cutaneous adverse events associated with GLP-1 agonists and explore possible reasons for differences between these drugs.
  • ||||||||||  liraglutide / Generic mfg.
    Journal:  Sustained Delivery of Liraglutide Using Multivesicular Liposome Based on Mixed Phospholipids. (Pubmed Central) -  Feb 26, 2025   
    However, when the SPC-DEPC ratio was 75:25, the BGC could be maintained below 16 mM for 8 days, indicating that the release properties of this ratio best met the pharmacological requirements of Lir. This study investigated the effects of phospholipids with different PTT on the release characteristics of Lir-MVLs, and provided ideas for the design of sustained-release peptide preparations.
  • ||||||||||  liraglutide / Generic mfg.
    Journal, Adverse events, Serious adverse event:  Analysis of Reporting Trends of Serious Adverse Events Associated With Anti-Obesity Drugs. (Pubmed Central) -  Feb 25, 2025   
    On the contrary, a continuous increase in the reporting rate of non-serious adverse drug events was observed only for liraglutide (annual change?+?33.8%, p?=?0.000) while for the other anti-obesity drugs, including semaglutide, the trends after the initial period were either negative or did not increase significantly. In conclusion, among the anti-obesity drugs currently approved, only semaglutide shows a continuously increasing trend in the annual reporting of serious adverse events, suggesting a need for further investigation of safety signals.
  • ||||||||||  liraglutide / Generic mfg.
    Review, Journal:  Obesity in Hidradenitis Suppurativa: Are GLP-1 Receptor Agonists the New Frontier? (Pubmed Central) -  Feb 24, 2025   
    Early studies of liraglutide and semaglutide in HS have demonstrated improvement in disease severity and quality of life. GLP-1 receptor agonists are a promising therapy for patients with HS and may improve symptoms through decreased mechanical stress and moderation of inflammation.
  • ||||||||||  liraglutide / Generic mfg.
    Journal:  Effects of liraglutide on body composition in people living with obesity or overweight: A systematic review. (Pubmed Central) -  Feb 22, 2025   
    However, the inability to accurately calculate lean and fat mass proportions underscores the need for standardized reporting and availability of individual-level data. Future research should prioritize these elements and include muscle function assessments to better evaluate the clinical impacts of GLP-1 receptor agonists on body composition.
  • ||||||||||  liraglutide / Generic mfg.
    The Role of GLP-1 Agonists in Overweight and Obese Hidradenitis Suppurativa Patients: A Retrospective Analysis () -  Feb 21, 2025 - Abstract #AAD2025AAD_2537;    
    Hidradenitis suppurativa (HS) is a chronic, multifactorial inflammatory disease that is influenced by obesity and metabolic dysfunction.[1] Studies examining the role of GLP-1 agonists in overweight and obese HS patients are limited to one case report in which an obese patient experienced disease improvement following liraglutide administration.[1,2] We performed a retrospective chart review to identify adult patients with an HS diagnosis and overweight/obesity who received a GLP-1 agonist prescription at a tertiary academic hospital between 01/01/2019-12/31/2023...The potential efficacy of GLP-1 agonists in the treatment of HS, while promising, requires further study. Weight loss alone may not fully explain the benefits of GLP-1 agonists in HS patients and further investigation into the therapeutic mechanisms are needed.
  • ||||||||||  Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie, Cosentyx (secukinumab) / Novartis
    Semaglutide Weight Loss Effects on Hidradenitis Suppurativa Severity (Orange County Convention Center (West Building, Exhibit Hall B4, Poster Center 1)) -  Feb 21, 2025 - Abstract #AAD2025AAD_2298;    
    Patients on liraglutide were excluded...Proxies for HS severity, such as the number of emergency room (ER) visits and the utilization of antibiotics (doxycycline, minocycline, azithromycin, erythromycin, clindamycin, clarithromycin, metronidazole, and rifampin), biologics (infliximab, adalimumab, and secukinumab), and steroids (hydrocortisone, prednisone, betamethasone, budesonide, methylprednisolone, dexamethasone, and triamcinolone) were used to calculate risk ratios...Patients on semaglutide showed a decrease use of antibiotics (RR 0.606, CI 0.579-0.633, p < 0.0001), biologics (RR 0.618, CI 0.512-0.746, p < 0.0001), steroids (RR 0.674, CI 0.646-0.704, p < 0.0001), and ER visits (RR 0.54, CI 0.508-0.575, p < 0.0001). Conclusion The results suggest that HS patients on semaglutide demonstrate reduced HS severity.
  • ||||||||||  Clinical, Retrospective data, Journal:  Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials. (Pubmed Central) -  Feb 21, 2025   
    Semaglutide, combining potent cardio-metabolic effects with oral route, emerges as a pivotal treatment for high-risk Type 2 diabetes patients, offering comprehensive CV protection independent of HbA1c levels. The FDA has approved glucagon-like peptide-1 (GLP-1) receptor agonists such as Liraglutide, Semaglutide, and the GLP-1/gastric inhibitory polypeptide (GIP) dual agonist Tirzepatide for the treatment of obesity...The maximum weight reduction effect ranged from 4.25
  • ||||||||||  liraglutide / Generic mfg.
    Review, Journal:  Are glucagon-like peptide-1 receptor agonists anti-consummatory drugs? (Pubmed Central) -  Feb 19, 2025   
    Incretin-based treatments, such as glucagon-like peptide-1 receptor (GLP-1R) agonists (eg liraglutide and semaglutide), have rapidly transformed obesity treatment...We also consider the physiological and neurobiological underpinnings of GLP-1 actions, with a focus on its distinct central and peripheral roles, as well as its relationships with the broader energy homeostasis network. We conclude with a discussion on the implications of this line of research on how behavior is conceptualized, and the potential future directions for research.